Pfizer projects mRNA vaccine sales will hover around $15B by 2030

Pfizer’s mRNA vaccines have been a high point for the company during the pandemic, and even with dwindling demand and government resources, the pharma is predicting $10 billion to $15 billion in annual revenue by 2030 for its mRNA vaccine portfolio (including Comirnaty, flu, the combo of Covid-flu, and shingles).